Rivaroxaban is an anticoagulant drug. These drugs can highly selectively and competitively inhibit free and bound factor Xa and prothrombin activity, and are used to prevent deep vein thrombosis and pulmonary embolism in patients after hip and knee replacement, as well as to prevent stroke and non-central nervous system embolism in patients with non-valvular atrial fibrillation and to reduce the risk of recurrence of coronary syndromes, etc. The decision to stop or not to stop the drug needs to be reviewed at the hospital, depending on the nature of the disease itself and the duration of oral rivaroxaban.